Cargando…

Type 2 Diabetes and Cardiovascular Disease: Reducing the Risk

BACKGROUND: Type 2 diabetes (T2DM) is a major risk factor for developing cardiovascular disease (CVD). The growing epidemic of T2DM has contributed to CVD becoming the leading cause of morbidity and mortality in the United States. OBJECTIVES: To review the pathophysiology of CVD; to demonstrate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Bartels, David W., Davidson, Michael H., Gong, William C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2007
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437557/
https://www.ncbi.nlm.nih.gov/pubmed/17330977
http://dx.doi.org/10.18553/jmcp.2007.13.s2-a.1
_version_ 1785092553505243136
author Bartels, David W.
Davidson, Michael H.
Gong, William C.
author_facet Bartels, David W.
Davidson, Michael H.
Gong, William C.
author_sort Bartels, David W.
collection PubMed
description BACKGROUND: Type 2 diabetes (T2DM) is a major risk factor for developing cardiovascular disease (CVD). The growing epidemic of T2DM has contributed to CVD becoming the leading cause of morbidity and mortality in the United States. OBJECTIVES: To review the pathophysiology of CVD; to demonstrate the interrelatedness of CVD, the metabolic syndrome, and T2DM; and to discuss treatment options that may reduce the risk of CVD in patients with T2DM. SUMMARY: Recent data from the International Diabetes Federation show that the worldwide prevalence of T2DM is much higher than previously estimated. Managing patients with T2DM continues to severely burden the U.S. health care system. Furthermore, most costs associated with managing these patients are associated with treating CVD complications. Studies have shown that several agents can decrease the risk of CVD in patients with T2DM. CONCLUSIONS: To combat the diabetes epidemic, clinicians should treat patients with T2DM and prediabetes early and aggressively to control their metabolic disturbances and reduce the risk of CVD. Diet, exercise, and several pharmacologic agents have been shown to reduce the risk of CVD.
format Online
Article
Text
id pubmed-10437557
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher Academy of Managed Care Pharmacy
record_format MEDLINE/PubMed
spelling pubmed-104375572023-08-21 Type 2 Diabetes and Cardiovascular Disease: Reducing the Risk Bartels, David W. Davidson, Michael H. Gong, William C. J Manag Care Pharm Supplement BACKGROUND: Type 2 diabetes (T2DM) is a major risk factor for developing cardiovascular disease (CVD). The growing epidemic of T2DM has contributed to CVD becoming the leading cause of morbidity and mortality in the United States. OBJECTIVES: To review the pathophysiology of CVD; to demonstrate the interrelatedness of CVD, the metabolic syndrome, and T2DM; and to discuss treatment options that may reduce the risk of CVD in patients with T2DM. SUMMARY: Recent data from the International Diabetes Federation show that the worldwide prevalence of T2DM is much higher than previously estimated. Managing patients with T2DM continues to severely burden the U.S. health care system. Furthermore, most costs associated with managing these patients are associated with treating CVD complications. Studies have shown that several agents can decrease the risk of CVD in patients with T2DM. CONCLUSIONS: To combat the diabetes epidemic, clinicians should treat patients with T2DM and prediabetes early and aggressively to control their metabolic disturbances and reduce the risk of CVD. Diet, exercise, and several pharmacologic agents have been shown to reduce the risk of CVD. Academy of Managed Care Pharmacy 2007-03 /pmc/articles/PMC10437557/ /pubmed/17330977 http://dx.doi.org/10.18553/jmcp.2007.13.s2-a.1 Text en Copyright © 2007, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Supplement
Bartels, David W.
Davidson, Michael H.
Gong, William C.
Type 2 Diabetes and Cardiovascular Disease: Reducing the Risk
title Type 2 Diabetes and Cardiovascular Disease: Reducing the Risk
title_full Type 2 Diabetes and Cardiovascular Disease: Reducing the Risk
title_fullStr Type 2 Diabetes and Cardiovascular Disease: Reducing the Risk
title_full_unstemmed Type 2 Diabetes and Cardiovascular Disease: Reducing the Risk
title_short Type 2 Diabetes and Cardiovascular Disease: Reducing the Risk
title_sort type 2 diabetes and cardiovascular disease: reducing the risk
topic Supplement
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437557/
https://www.ncbi.nlm.nih.gov/pubmed/17330977
http://dx.doi.org/10.18553/jmcp.2007.13.s2-a.1
work_keys_str_mv AT bartelsdavidw type2diabetesandcardiovasculardiseasereducingtherisk
AT davidsonmichaelh type2diabetesandcardiovasculardiseasereducingtherisk
AT gongwilliamc type2diabetesandcardiovasculardiseasereducingtherisk